/A
Phase 1
- Conditions
- MedDRA version: 14.0 Level: PT Classification code 10036476 Term: Prader-Willi syndrome System Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
- Registration Number
- EUCTR2011-003432-32-FR
- Lead Sponsor
- ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 125
Inclusion Criteria
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Prader-Willi syndrome genetic mechanisms therapeutic targets SNORD116 MAGEL2 drug development
Phase 1 clinical trials Prader-Willi syndrome novel therapies safety pharmacokinetics
Biomarkers Prader-Willi syndrome diagnosis treatment response ghrelin leptin oxytocin
Prader-Willi syndrome hyperphagia treatment clinical trials GLP-1 agonists oxytocin analogues
EUCTR2011-003432-32-FR TOPRADER Prader-Willi syndrome AP-HP clinical trial results publications